I5X Stock Overview Operates as a discovery and clinical-stage biopharmaceutical company that develops gene and cell therapies using precision technology to target diseases in therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. More details
Rewards Risk Analysis See All Risk Checks Capture your thoughts, links and company narrative
Precigen, Inc. Competitors Price History & Performance
Summary of share price highs, lows and changes for Precigen Historical stock prices Current Share Price US$1.10 52 Week High US$1.80 52 Week Low US$0.63 Beta 1.65 1 Month Change 50.55% 3 Month Change 47.02% 1 Year Change -16.74% 3 Year Change -59.51% 5 Year Change -79.06% Change since IPO -92.85%
Recent News & Updates
Precigen, Inc. announced that it has received $79 million in funding Jan 01 Precigen, Inc. announced that it has received $79 million in funding Dec 31
Precigen Completes Submission of BLA with Request for Priority Review to the FDA for PRGN-2012 for the Treatment of Adults with Recurrent Respiratory Papillomatosis Dec 30
Precigen, Inc. announced that it expects to receive $79 million in funding Dec 29 Precigen, Inc. announced that it expects to receive $79 million in funding Dec 28
Third quarter 2024 earnings released: US$0.087 loss per share (vs US$0.08 loss in 3Q 2023) Nov 15 See more updates
Precigen, Inc. announced that it has received $79 million in funding Jan 01 Precigen, Inc. announced that it has received $79 million in funding Dec 31
Precigen Completes Submission of BLA with Request for Priority Review to the FDA for PRGN-2012 for the Treatment of Adults with Recurrent Respiratory Papillomatosis Dec 30
Precigen, Inc. announced that it expects to receive $79 million in funding Dec 29 Precigen, Inc. announced that it expects to receive $79 million in funding Dec 28
Third quarter 2024 earnings released: US$0.087 loss per share (vs US$0.08 loss in 3Q 2023) Nov 15
Precigen Receives Non-Compliance Letter from Nasdaq Regarding Bid Price Rule Nov 09
Precigen Receives Non-Compliance Letter from Nasdaq Regarding Bid Price Rule Nov 08
Second quarter 2024 earnings released: US$0.23 loss per share (vs US$0.082 loss in 2Q 2023) Aug 15 Precigen, Inc. to Report Q2, 2024 Results on Aug 14, 2024
New minor risk - Shareholder dilution Aug 08 Precigen, Inc. has completed a Follow-on Equity Offering in the amount of $30 million. Aug 08
Precigen, Inc. has filed a Follow-on Equity Offering in the amount of $30 million.
New major risk - Share price stability Jul 24
Precigen, Inc. Announces the Appointment of Phil Tennant as Chief Commercial Officer Jul 23
New major risk - Share price stability Jun 07
Precigen, Inc. Announces Groundbreaking Pivotal Study Data for PRGN-2012 in Patients with Recurrent Respiratory Papillomatosis in Which More Than Half of Patients Achieved Complete Response Jun 05
Precigen, Inc., Annual General Meeting, Jul 05, 2024 May 31
First quarter 2024 earnings released: US$0.095 loss per share (vs US$0.099 loss in 1Q 2023) May 15
Precigen, Inc. to Report Q1, 2024 Results on May 14, 2024 May 10
Precigen, Inc. to Present Late-Breaking Abstract for Pivotal Phase 2 Study Data for PRGN- 2012 AdenoVerse Immunotherapy Apr 25
Full year 2023 earnings released: US$0.39 loss per share (vs US$0.40 loss in FY 2022) Mar 20
Precigen, Inc. to Report Q4, 2023 Results on Mar 19, 2024 Mar 06
Precigen, Inc. Receives Orphan Drug Designation for PRGN- 2012 for the Treatment of Recurrent Respiratory Papillomatosis from the European Commission Jan 17
Forecast to breakeven in 2026 Dec 31
New minor risk - Profitability Nov 11
Third quarter 2023 earnings released: US$0.08 loss per share (vs US$0.038 loss in 3Q 2022) Nov 10
Independent Director recently bought €630k worth of stock Aug 16
Precigen, Inc Announces FDA Confirmation that the Ongoing Phase 1/2 Study of PRGN-2012 AdenoVerse Immunotherapy Will Serve as the Pivotal Study to Support Accelerated Approval Aug 10
Second quarter 2023 earnings released: US$0.082 loss per share (vs US$0.13 loss in 2Q 2022) Aug 10 Precigen, Inc. to Report Q2, 2023 Results on Aug 09, 2023 Aug 04
Precigen, Inc. Receives Breakthrough Therapy Designation for PRGN- 2012 Adenoverse Immunotherapy for the Treatment of Recurrent Respiratory Papillomatosis Jun 22
Precigen Announces Positive Phase 1 Data for PRGN-3005 Autologous UltraCAR-T Cells Manufactured Overnight for Infusion Next Day to Advanced Stage Platinum Resistant Ovarian Cancer Patients Jun 06
Precigen Announces Positive Phase 1 Data for Off-the-Shelf PRGN-2009 AdenoVerse Immunotherapy Alone and in Combination with an Investigational Checkpoint Inhibitor in Patients with Recurrent/Metastatic HPV-associated Cancers Jun 04 Precigen, Inc. Receives FDA Clearance of IND to Initiate Phase 2 Study of PRGN-2009 Off-the Shelf AdenoVerse Immunotherapy in Combination with Pembrolizumab to Treat Patients with Recurrent or Metastatic Cervical Cancer Jun 01
First quarter 2023 earnings released: US$0.099 loss per share (vs US$0.12 loss in 1Q 2022) May 11
Precigen, Inc. to Report Q1, 2023 Results on May 10, 2023 May 04 Precigen, Inc. has completed a Follow-on Equity Offering in the amount of $75 million.
Precigen, Inc. Provides Pipeline and Corporate Updates at the 41st Annual J.P. Morgan Healthcare Conference Jan 12
Now 20% undervalued after recent price drop Jan 12
Precigen, Inc. Announces Positive Phase 1 Dose Escalation Data for Autologous PRGN-3006 UltraCAR-T Manufactured Overnight for Next Day Infusion in Relapsed or Refractory Acute Myeloid Leukemia Patients Dec 15
Insufficient new directors Nov 16
Third quarter 2022 earnings released: US$0.038 loss per share (vs US$0.15 loss in 3Q 2021) Nov 11
Precigen, Inc. to Report Q3, 2022 Results on Nov 09, 2022 Nov 03
Precigen, Inc. Appoints Rutul R. Shah as Chief Operating Officer, Effective October 1, 2022 Sep 22
Chief Financial Officer recently bought €51k worth of stock Aug 25
Independent Director recently sold €111k worth of stock Aug 16
Second quarter 2022 earnings released: US$0.13 loss per share (vs US$0.10 loss in 2Q 2021) Aug 09
Precigen, Inc. to Report Q2, 2022 Results on Aug 08, 2022 Aug 02
URUS Group LP agreed to acquire Trans Ova Genetics LC from Precigen, Inc. (NasdaqGS:PGEN) for $180 million. Jul 06
First quarter 2022 earnings released: US$0.096 loss per share (vs US$0.11 loss in 1Q 2021) May 11 Precigen, Inc. Announces Impairment of Goodwill for Three Months Ended March 31, 2022 May 10
Precigen, Inc. to Report Q1, 2022 Results on May 09, 2022 May 05
Precigen, Inc., Annual General Meeting, Jun 09, 2022 May 02
Insufficient new directors Apr 27
Precigen, Inc. Receives Fast Track Designation for PRGN-3006 UltraCAR-T® in Patients with Relapsed or Refractory Acute Myeloid Leukemia Apr 06
Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat Mar 02
Precigen, Inc. to Report Q4, 2021 Results on Mar 01, 2022 Feb 25
Precigen, Inc Announces Positive Interim Phase 1 Data for PRGN-3006 UltraCAR-T® in Relapsed or Refractory Acute Myeloid Leukemia Dec 15
Insufficient new directors Dec 06
Executive Chairman recently bought €3.2m worth of stock Dec 01
Third quarter 2021 earnings released: US$0.15 loss per share (vs US$0.18 loss in 3Q 2020) Nov 09
Second quarter 2021 earnings released: US$0.10 loss per share (vs US$0.26 loss in 2Q 2020) Aug 10
VP of Finance & Accounting and Principal Accounting Officer D. Osborne has left the company Jun 12
First quarter 2021 earnings released: US$0.11 loss per share (vs US$0.19 loss in 1Q 2020) May 12
Chief Financial Officer has left the company Apr 06
Revenue misses expectations Mar 07
Full year 2020 earnings released: US$0.62 loss per share (vs US$1.10 loss in FY 2019) Mar 07
Precigen, Inc. to Report Q4, 2020 Results on Mar 01, 2021 Feb 23
Precigen, Inc. has completed a Follow-on Equity Offering in the amount of $112.5 million. Jan 23
Precigen, Inc. Announces Clearance of IND to Initiate Phase I Study of PRGN-2012 AdenoVerse Immunotherapy in Patients with Recurrent Respiratory Papillomatosis Jan 06
New 90-day high: €8.85 Jan 04
Precigen, Inc. Provides Latest Clinical Developments At Virtual R&D Update Event Dec 17
Zhang Investor Law Alerts Investors to December 4 Deadline in Securities Class Action Lawsuit Against Precigen, Inc Dec 04
New 90-day high: €6.20 Nov 27
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been File Against Precigen, Royal Caribbean, Mesoblast and Loop Industries Nov 19
Precigen, Inc Announces Clinical Implementation of Its UltraPorator System Nov 18
Bernstein Liebhard Reminds Investors of the Deadline to File A Lead Plaintiff Motion in A Securities Class Action Lawsuit Against Precigen Inc Nov 13 Shareholder Returns I5X DE Biotechs DE Market 7D 8.7% 6.5% 1.3% 1Y -16.7% -1.9% 9.0%
See full shareholder returns
Return vs Market: I5X underperformed the German Market which returned 10.1% over the past year.
Price Volatility Is I5X's price volatile compared to industry and market? I5X volatility I5X Average Weekly Movement 19.5% Biotechs Industry Average Movement 7.3% Market Average Movement 4.9% 10% most volatile stocks in DE Market 11.6% 10% least volatile stocks in DE Market 2.4%
Stable Share Price: I5X's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: I5X's weekly volatility has increased from 13% to 19% over the past year.
About the Company Founded Employees CEO Website 1998 202 Helen Sabzevari precigen.com
Precigen, Inc. operates as a discovery and clinical-stage biopharmaceutical company that develops gene and cell therapies using precision technology to target diseases in therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. It operates through two segments, Biopharmaceuticals and Exemplar. The company offers therapeutic platforms consisting of UltraCAR-T to provide chimeric antigen receptor T cell therapies for cancer patients; AdenoVerse immunotherapy, which utilizes a library of proprietary adenovectors for gene delivery of therapeutic effectors, immunomodulators, and vaccine antigen; and ActoBiotics for specific disease modification.
Show more Precigen, Inc. Fundamentals Summary How do Precigen's earnings and revenue compare to its market cap? I5X fundamental statistics Market cap €337.33m Earnings (TTM ) -€136.23m Revenue (TTM ) €3.87m
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) I5X income statement (TTM ) Revenue US$3.96m Cost of Revenue US$53.07m Gross Profit -US$49.11m Other Expenses US$90.46m Earnings -US$139.56m
Last Reported Earnings
Sep 30, 2024
Earnings per share (EPS) -0.48 Gross Margin -1,239.14% Net Profit Margin -3,521.68% Debt/Equity Ratio 0%
How did I5X perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2025/01/10 07:25 End of Day Share Price 2025/01/10 00:00 Earnings 2024/09/30 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources Precigen, Inc. is covered by 13 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Ying Huang Barclays Derik de Bruin BofA Global Research Justin Walsh B. Riley Securities, Inc.
Show 10 more analysts 
